Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2024, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $199.69 million, up 110.3% over the same period last year. EPS came in at -$ 0.28, compared to - $1.02 in the year-ago quarter.The reported revenue represents a surprise of +5.39% over the Zacks Consensus Estimate of$ 189.47 million. With the consensus EPS estimate being -$0.33, the EPS surprise was +15.15%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...